MarketMoodz
Goldman sees CPI-818 could double CRVS on oral eczema drug
Goldman Sachs argues Corvus Pharmaceuticals’ CPI-818 (soquelitinib) could more than double the stock, setting a $40 target and signaling 166% upside. The note anchors on near-term catalysts and the Jan. 20 early-stage trial press release showing a 75% responder rate, and the stock rose about 9% on the news.
Key Takeaways
- Goldman Sachs sets a $40 price target for CRVS, implying roughly 166% upside.
- Corvus stock jumped about 9% on the Goldman call and is up roughly 113% year-to-date.
- CPI-818 (soquelitinib) showed a 75% responder rate in the Jan. 20 early-stage trial.
- Global atopic dermatitis market is projected to exceed $24B by 2035, underscoring multi-indication potential.
- Upcoming catalysts include additional trial readouts and potential regulatory milestones.
People Involved
- Paul Choi Goldman Sachs analyst
Entities Involved
- Corvus Pharmaceuticals (CRVS) Biopharma company developing CPI-818; mid-cap
- Goldman Sachs Investment bank issuing the note with price target
- CPI-818 (soquelitinib) Oral eczema drug candidate
MarketMoodz Analysis
Goldman’s note frames CPI-818 as a potential differentiator in a crowded non-steroidal/immune-oncology dermatology space. The $40 target and 166% upside imply the market is pricing a meaningful probability of binary-type success into CRVS. For investors, near-term catalysts such as the January 20 readout and any subsequent data releases are critical to validate the thesis.
Historically, mid-cap biotechs with single-asset pipelines hinge on a handful of catalysts to unlock value. A 75% responder rate in early-stage data is encouraging, but cohort size and responder criteria matter for durability and safety signals. The 24B+ global atopic dermatitis market by 2035 provides a substantial backdrop if CPI-818 demonstrates multi-indication potential. Watch how peers in dermatology and immune-oncology perform and how Corvus manages cash runway as it advances through trials.
What to watch next includes additional trial readouts, potential regulatory milestones, and any partnerships or licensing discussions that could broaden CPI-818’s addressable market and de-risk the program.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial